Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Rheumatoid Arthritis

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 17 articles:
HTML format



Single Articles


    January 2021
  1. HUMBY F, Durez P, Buch MH, Lewis MJ, et al
    Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
    Lancet. 2021;397:305-317.
    PubMed     Abstract available


  2. PODDUBNYY D
    Precision medicine in rheumatology: are we getting closer?
    Lancet. 2021;397:258-259.
    PubMed    


    July 2020
  3. BURMESTER GR, Buttgereit F, Bernasconi C, Alvaro-Gracia JM, et al
    Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
    Lancet. 2020;396:267-276.
    PubMed     Abstract available


  4. VOLKMANN ER
    Tapering glucocorticoids in rheumatoid arthritis.
    Lancet. 2020;396:218-219.
    PubMed    


    June 2019
  5. MOLTO A, Dougados M
    Novel DMARD monotherapy in rheumatoid arthritis.
    Lancet. 2019;393:2277-2278.
    PubMed    


    May 2019
  6. SMOLEN JS, Pangan AL, Emery P, Rigby W, et al
    Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
    Lancet. 2019 May 23. pii: S0140-6736(19)30419.
    PubMed     Abstract available


  7. FLUME PA, Chalmers JD, Olivier KN
    Rheumatoid arthritis-associated bronchiectasis - Authors' reply.
    Lancet. 2019;393:2036.
    PubMed    


  8. PUECHAL X, Bienvenu T, Dusser D
    Rheumatoid arthritis-associated bronchiectasis.
    Lancet. 2019;393:2035-2036.
    PubMed    


    September 2018
  9. HASANOV E, Fard EV, Puravath A, Johnston JS, et al
    T-cell large granular lymphocytic leukaemia in the context of rheumatoid arthritis.
    Lancet. 2018;392:1071.
    PubMed    


    June 2018
  10. GOLL GL, Kvien TK
    New-generation JAK inhibitors: how selective can they be?
    Lancet. 2018;391:2477-2478.
    PubMed    


  11. GENOVESE MC, Fleischmann R, Combe B, Hall S, et al
    Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Lancet. 2018 Jun 12. pii: S0140-6736(18)31116.
    PubMed     Abstract available


  12. BURMESTER GR, Kremer JM, Van den Bosch F, Kivitz A, et al
    Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet. 2018 Jun 12. pii: S0140-6736(18)31115.
    PubMed     Abstract available


    June 2017
  13. SCOTT DL, Stevenson MD
    Treating active rheumatoid arthritis with Janus kinase inhibitors.
    Lancet. 2017 Jun 15. pii: S0140-6736(17)31659.
    PubMed    


  14. FLEISCHMANN R, Mysler E, Hall S, Kivitz AJ, et al
    Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
    Lancet. 2017 Jun 15. pii: S0140-6736(17)31618.
    PubMed     Abstract available


  15. BURMESTER GR, Pope JE
    Novel treatment strategies in rheumatoid arthritis.
    Lancet. 2017;389:2338-2348.
    PubMed     Abstract available


  16. MCINNES IB, Schett G
    Pathogenetic insights from the treatment of rheumatoid arthritis.
    Lancet. 2017;389:2328-2337.
    PubMed     Abstract available


  17. LANE R
    Gerd Burmester: enduring leader in rheumatoid arthritis.
    Lancet. 2017;389:2279.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: